Michael J. Morris, MD, discusses the mechanism of action for AB001, PSMA-targeted radioligand therapy for patients with mCRPC.
Michael J. Morris, MD
Advertisement
Michael J. Morris, MD, is a medical oncologist and the prostate cancer section head at Memorial Sloan Kettering Cancer Center in New York, New York.
Articles by Michael J. Morris, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
